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AspergillosisAbstract Objective: The Dutch Hypothesis has been used to suggest that Asthma and COPD may
be considered as different expressions of one disease entity. The purpose of this study is to evaluate
the levels of IgE in COPD patients and its relation with respiratory symptoms and lung functions
this may be a suggestive of atopy as a mechanism for initiation of their exacerbations.
Methods: A cross-sectional case-control study was conducted on 50 subjects recruited from the
outpatient clinic (11 healthy volunteers, 39 diagnosed as COPD) COPD patients (31 males (79%)
and 8 females (21%)) diagnosed as mild, moderate and severe. The studied groups were also divided
according to total serum IgE levels and compared in demographic data, clinical data, spirometric
data, and HRCT ﬁndings.
Results: COPD patients with elevated IgE had a longer history of illness, high smoking index,
higher number of exacerbation in the last year, and more lower FEV1.
HRCT ﬁnding in both groups was hyperinﬂation was high in COPD patients with normal IgE
levels, 10 cases (45%), while bronchiectasis was higher in COPD patients with elevated IgE, 7 cases
(41%). Sputum culture was positive for aspergillosis in 5 cases (29%) in COPD patients with
elevated IgE.
Conclusions: There was a high prevalence of elevated serum T-IgE in patients with COPD but
without obvious atopy. Serum T-IgE levels were found to be associated with symptoms such as
dyspnea and impairment of lung function. Recurrent exacerbation of COPD is believed to acceler-
ate disease progression and impairment of pulmonary function.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
COPD is a heterogeneous disease and can be classiﬁed into dif-
ferent ‘‘phenotypes’’ [1]. COPD is a disorder of progressiveairﬂow limitation caused by chronic inﬂammation of the air-
ways and lung parenchyma and associated with symptoms
such as cough, sputum production, and dyspnea. Smoking is
the primary risk factor for the development of COPD.
Worldwide, it ranks as the fourth leading cause of death,
alongside HIV/AIDS. By the year 2020, COPD is predicted
to become the third leading cause of death worldwide
(exceeded only by heart disease and stroke) [2].rculosis.
574 H.M.S. Samaha et al.Exacerbations of asthma often have identiﬁable triggers
such as allergens, cold air, or exercise. However, exacerbations
in COPD patients are commonly caused by respiratory tract
infections. Both these diseases were once considered to be at
the opposite ends of the spectrum of airway disease, where
asthma was thought to be highly responsive to treatment
and essentially reversible; COPD was characterized by ﬁxed
airway narrowing and unresponsive to the treatment. The cur-
rently accepted deﬁnitions still emphasize these features, but
there may be a signiﬁcant overlap between the two diseases.
Today it is recognized that these two conditions are distinct
but their clinical features overlap and it is often difﬁcult to dif-
ferentiate, clinically diagnose, and classify the two disorders
[3,4]. The Dutch Hypothesis has been used to suggest that
Asthma and COPD may be considered as different expressions
of one disease entity. The purpose of this study is to evaluate
the levels of IgE in COPD patients and its relation with res-
piratory symptoms and lung functions. This may be a sugges-
tive of atopy as a mechanism for initiation of their
exacerbations.
Methods
A cross-sectional case-control study was conducted on 50
subjects recruited from the outpatient clinic (11 healthy
volunteers, 39 diagnosed as COPD) between October 2011
and February 2013 COPD patients (31 males (79%) and 8
females (21%)) were diagnosed and classiﬁed as mild,
moderate and severe. COPD classiﬁcation as mild, moderate
and severe disease was established according to GOLD
criteria [5] (FEV1/FVC was <0.70 and post-bronchodilator
FEV1 was >80% from predictive value in mild COPD, while
moderate FEV1 50–79% and severe FEV1 30–49%). All
patients were subjected to a complete history taking and
physical examination, complete blood count (total leucocytic
count and absolute eosinophilic count), high resolution CT,
pulmonary function tests, urine and stool analysis sputum
culture for bacterial or fungal infection and serum total IgE
levels. Patients accepted to participate by giving informed
consent.
The patients were diagnosed to have COPD by the
following criteria: (i) age more than 40 years, (ii) chronic
cough, expectoration and/or wheeze for at least three
months in a year for two successive years, (iii) currently
smoking or having a history of smoking (smoking indexP 10
pack-year), and/evidence of irreversible obstructive impair-
ment on spirometry deﬁned by a postbronchodilator FEV1/
FVC< 70%.
The enrolled patients were required to have no history of
doctor-diagnosed allergy such as allergic rhinitis and eczema,
no obvious food allergy, no family history of asthma, and no
evidence of parasite infection. The enrolled patients with
COPD should have no acute exacerbation of COPD within
at least 2 weeks [6].
Patients were excluded from the study if they met any of the
following criteria: (1) receiving systemic steroid therapy in the
preceding 4 weeks, (2) receiving any other immunosuppressive
therapy, (3) with active pulmonary tuberculosis, interstitial
lung disease, and severe heart failure, (4) not adherent to med-
ication (5) uncontrolled diabetes mellitus, thyroid disorders (6)
no exacerbation in the last month.During history taking cough and expectoration, dyspnea
wheezes and number of exacerbation attacks in the last year.
Exertional dyspnea was identiﬁed as present if the mMRC
(Modiﬁed Medical Research Council Questionnaire) score
was equal to or more than 2 [7]. The duration of history of a
symptom, for example, the duration of dyspnea history, was
deﬁned as the duration from the onset of the symptom to
enrollment in the study. As in patients with COPD, chronic
cough and expectoration generally precede exertional dyspnea
for a different period of time, and dyspnea is a major cause of
disability and anxiety associated with the disease.
Pulmonary function test
Spirometry (BTL-08 spiro, Germany) was performed to deter-
mine the lung function measurements and bronchodilator
reversibility. Post-bronchodilator FEV1/FVC% and FEV1
were measured 15 min after inhalation of 400 lg of salbutamol.
HRCT of the chest and determination of central bronchiectasis
HRCT of the chest were performed using a 64-row, multiple
detector CT scanner (Philips Company, Netherlands). The
diagnosis of bronchiectasis on chest HRCT was made if bron-
chial wall thickening was present with the ratio of the diameter
of the bronchus to that of the accompanying pulmonary artery
is more than 1.1 (signet ring sign), or the lack of tapering of
bronchi (tramline sign). Central bronchiectasis was deﬁned
as the presence of bronchiectasis in the central two thirds of
the lung ﬁeld [8,9].
Detection of serum T-IgE
Total T-IgE level was estimated using chemiluminescent
microparticle immunoassay (ARCHITECT c4000-Abott
diagnostics, Abott laboratories USA). It was determined as
elevation if serum T-IgE > 100 IU/L. Hematocrit value, total
leukocyte count eosinophil count and neutrophil were initially
determined using an auto-analyzer.
Statistical analysis
All statistical analyses were performed using a statistical soft-
ware package (Statistics Package for the Social Sciences, SPSS
16.0). Data are expressed as the mean ± SD (standard devia-
tion). Comparisons of continuous data between two groups
were performed by T-test (for normal distribution parameters)
and Mann–Whitney U test (for abnormal distribution parame-
ters). Comparisons of continuous data among three groups
were performed by an ANOVA test (for normal distribution)
or Kruskal Wallis test (for abnormal distribution).
Categorical variables between different groups were analyzed
by v2 test. Spearman Correlations were used for correlation
analysis. P values less than 0.05 were considered as statistically
signiﬁcant.
Results
During the study period we studied 50 subjects recruited from
the outpatient clinic (11 healthy volunteers, 39 diagnosed as
IgE and COPD 575COPD). COPD patients (31 males (79%) and 8 females
(21%)). 15 patients (38%) with Mild COPD stage I, 15
patients (38%) moderate COPD stage II and 9 patients
(24%) severe COPD stage III disease classiﬁcation was estab-
lished according to GOLD criteria 5.
All group patients were age and sex matched without a sig-
niﬁcant difference. There was a signiﬁcant difference between
studied groups regarding clinical indices (duration of illness,
wheezes, cough and expectoration, wheezes, current smoking
status, smoking index and number of exacerbation attacks in
the last year).
Serum T-IgE levels were signiﬁcantly higher in COPD
patients than control subjects (see Table 1).
HRCT showed normal ﬁnding in 53% of cases in group I,
bronchiectasis in 40% of cases in group II and hyperinﬂation
in 56% of cases in group III.
Sputum culture sensitivity was positive for candida in 2
cases (13%), 3 cases (20%), and 2 cases (22%) in group I, II,
and III respectively. Aspergillosis was detected in only 3 cases
(20%), 2 cases (22%) in group II and III respectively. Other
bacteria like Klebsiella and Pseudomonas were detected in 3
cases (33%) in group III.
Table 2 shows the comparison between COPD patients with
elevated serum T-IgE and those with normal serum T-IgE.
There was no signiﬁcant difference in gender, age, dyspnea,
cough and expectoration, wheezes, smoking history betweenTable 1 Comparsion between studied groups in clinical, laboratory
Group I
(stage I)N= 15
Group II
(stage II)N=
Age 52 ± 7.8 51 ± 4.5
Sex
Male 12 (80%) 12 (80%)
Female 3 (20%) 3 (20%)
Dyspnea 7 (47%) 11 (73%)
Cough and expectoration 13 (87%) 14 (93%)
Wheezes 4 (27%) 6 (40%)
Smoker
Ex smoker 7 (47%) 6 (40%)
Smoking index 8 (0–20) 30 (0–84)
Duration of illness 4.6 ± 1.3 8.7 ± 3.2
Number of
exacerbation attacks/last year 2 (0–5) 4 (0–9)
FEV1 87 ± 3.9 72 ± 4.8
IgE level 65 (25–150) 178 (56–3993
HRCT
Normal 8 (53%) 1 (6%)
Hyperinﬂation 5 (35%) 4 (27%)
Mosaic perfusion 1 (6%) 4 (27%)
Bronchiectasis 1 (6%) 6 (40%)
Hematocrit value 46 ± 3.1 45 ± 3.4
Eosinophilic count 3.4 ± 1.3 3.5 ± 1.5
Neutrophil % 51 ± 9.6 56 ± 8.2
Leucocytic count 8.7 ± 2 8.5 ± 2.2
Sputum C/S
Aspergillosis 0 (0%) 3 (20%)
Candidia 2 (13%) 3 (20%)
Bacteria 0 (0%) 0 (0%)the group with elevated IgE, (n= 17) (group B) and that with
normal IgE levels, group A (n= 22).
Compared with the normal IgE group A, patients with ele-
vated IgE group B had a longer history of illness, high smoking
index, higher number of exacerbation in the last year, and
more lower FEV1.
HRCT ﬁnding in both groups was: hyperinﬂation was high
in group A, 10 cases (45%), while bronchiectasis was higher in
group B, 7 cases (41%). Sputum culture was positive for
aspergillosis in 5 cases (29%) in group B.
Candida was positive in 4 cases (18%) in group A and 3
cases (18%) group B. Other bacteria like Klebsiella and
Pseudomonas were detected in 3 cases (18%) in group B.
Table 3 shows correlation coefﬁcient analysis of serum total
IgE levels and clinical parameters of COPD patients. Serum
total IgE was shown to be correlated positively with dyspnea,
cough and expectoration, wheezes, smoking index, duration of
symptoms and number of acute exacerbation in the last years.
Table 4 shows correlation coefﬁcient analysis of serum total
IgE levels and GOLD staging, FEV1, HRCT ﬁnding and other
laboratory investigations in all COPD patients. There was a
weak negative correlation between serum total IgE levels and
GOLD staging of COPD, FEV1 and eosinophilic count.
Serum total IgE levels were correlated strongly with HRCT
ﬁndings. Finding of sputum culture was correlated with serum
total IgE levels.and radiological ﬁndings.
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Group III
(stage III)N= 9
Group I
(control)N= 11
P value
54 ± 8.8 54 ± 7.6 P> 0.05
7 (78%) 9 (82%) P> 0.05
2 (22%) 2 (18%)
7 (78%) 0 P< 0.001
9 (100%) 0 P< 0.001
7 (78%) 0 P< 0.001
1 (11%) 0 P< 0.001
40 (0–70) 0 P< 0.05
11.5 ± 5.1 0 P< 0.001
7 (0–10) 0 P< 0.05
46 ± 1.9 93 ± 2.3 P< 0.001
) 237 (43–1929) 20 (2–30) P< 0.01
0 (0%) 11 (100%)
5 (56%) 0 P< 0.001
3 (33%) 0
1 (11%) 0
46 ± 3.9 44 ± 2.1 P> 0.05
3.3 ± 1.6 3.3 ± 1.2 P> 0.05
46 ± 9.6 53 ± 6.4 P> 0.05
8 ± 1.5 8.6 ± 2 P> 0.05
2 (22%)
2 (22%) 0 P< 0.001
3 (33%)
Table 2 Comparison between studied COPD patients accord-
ing to IgE levels.
Group A Group B P value
N= 22
(56%)
N= 17
(44%)
COPD with
normal IgE
COPD with
elevated IgE
Age 53 ± 7.7 51 ± 5.8 P> 0.05
Sex
Male 17 (77%) 14 (82%) P> 0.05
Female 5 (23%) 3 (18%)
Dyspnea 11 (50%) 14 (82%) P> 0.05
Cough and
expectoration
19 (86%) 17 (100%) P> 0.05
Wheezes 6 (27%) 11 (65%) P> 0.05
Ex-smoker 10 (45%) 4 (24%) P> 0.05
Smoking index 20 (0–60) 40 (0–84) P< 0.01
Duration of illness 4.5 ± 1.3 11.1 ± 3.6 P< 0.001
Number of
exacerbation attacks/
last year
0 (0–10) 6 (2–9) P< 0.01
FEV1 78 ± 1.5 65 ± 1.4 P< 0.01
HRCT
Normal 9 (41%) 0 (0%)
Hyperinﬂation 10 (45%) 4 (24%)
Mosaic perfusion 2 (9%) 6 (35%) P< 0.001
Bronchiectasis 1 (5%) 7 (41%)
Hematocrit value 47 ± 3.4 44 ± 3.2 P> 0.05
Eosinophilic count 3.4 ± 1.5 3.5 ± 1.7 P> 0.05
Neutrophil% 52 ± 8.9 52 ± 15.8 P> 0.05
Leucocytic count 8.3 ± 1.9 9.2 ± 2.1 P> 0.05
Sputum C/S
Aspergillosis 0 (0%) 5 (29%) P< 0.001
Candidia 4 (18%) 3 (18%)
Bacteria 0 (0%) 3 (18%)
576 H.M.S. Samaha et al.Discussion
Our study showed for the ﬁrst time to our knowledge that
increased serum total IgE is a sensitive marker for allergy,
COPD patients with higher smoking index, longer duration
of illness, more severe lung function impairment, more with
patient with repeated frequent exacerbation. Also there was
a strong association between high levels of total serum IgE
levels and sputum culture which reveals positive for aspergillo-
sis, Candida albicans, and other bacteria like Klebsiella, and
Pseudomonas.
Previous studies have demonstrated that allergy was asso-
ciated with decreased lung function in general population,
smokers and mild COPD patients [10–13].
The increased serum levels of T-IgE may result from aller-
gic inﬂammation at other parts of the host, and may be asso-
ciated with genetic factors and even smoking history [14,15].Table 3 Correlation coefﬁcients between serum total IgE levels and
Age Sex Dyspnea Cough and
expectoration
Wheezes Smok
r .07 .03 0.4 0.3 0.5 0.3
P >0.05 >0.05 <0.01 <0.05 <0.001 <0.0In our study, the increased levels of serum IgE were consid-
ered to mostly reﬂect the allergic inﬂammation of the airways.
Firstly, the prevalence and the levels of IgE elevation were
much lower in the control population when compared with
those of the COPD patients. Secondly, no allergic inﬂamma-
tion of other systems such as the skin was noted, and parasite
infection was excluded in our study subjects according to his-
tory taking, physical examination and accessory examinations.
The results demonstrated that the prevalence of elevated
serum T-IgE was 44% (17/39) in patients with COPD, imply-
ing that even among COPD patients without obvious atopy,
hypersensitive inﬂammation of the lower airways may exist,
probably representing the real proportion of the allergic
phenotype in patients with COPD. Much higher prevalence
is reported as compared to those reported by Jamieson et al.
[16] and Bafadhel et al. [17].
The reason for the difference may be easily understood,
since, the criteria for ‘‘allergy’’ were different. Just as mentioned
above, measurement of serumT-IgEmay bemore sensitive than
results of speciﬁc IgE.
ABPA in COPD patients is receiving considerable interest.
Agarwal et al. reported that the prevalence of Aspergillus sen-
sitization and ABPA in a the cohort of COPD patients without
atopy was 8.5% and 1% respectively [14], while in the study by
Bafadhel et al. the prevalence of Aspergillus sensitization in
COPD was 13% [17]. Our study showed that the prevalence
of Aspergillus in sputum of COPD with IgE levels was
29%.This discrepancy may be due to different study subjects,
different methods to determine Aspergillus.
We also found that sputum culture was positive for C. albi-
cans in both groups with high or low IgE levels and its level in
both groups was 18%.
Other bacteria like Klebsiella, Pseudomonas were detected
in 3 cases (18%) in COPD with higher total serum IgE.
We found no signiﬁcant difference in the history length of
chronic cough/expectoration, wheezes and smoking history
between patients with elevated serum IgE and those with
normal serum IgE, but smoking index showed a signiﬁcant
difference between both groups.
We showed that COPD patients with elevated serum IgE
suffered for a longer duration of illness, had an earlier onset
of dyspnea on the background of chronic cough/sputum,
higher smoking index, higher number of frequent exacerbation
in the last year and had a worse lung function.
This suggested that serum IgE levels might, to some degree,
have an effect on the progression of COPD, or could be a
useful marker to reﬂect the severity of disease.
Since asthma and COPD shared some pathological charac-
teristics [18], we speculated that elevated serum T-IgE might
promote the airway inﬂammation and remodeling, and then
resulted in more serious symptoms and worse status of lung
function. So we must assess the levels of IgE in obstructive air-
way diseases and classifying them according to its level.clinical indices in all COPD patients.
ing Smoking
index
Duration of
symptoms
No. of acute attacks/last
year
0.7 0.4 0.4
5 <0.001 <0.01 <0.01
Table 4 Correlation coefﬁcients between serum total IgE levels and GOLD staging, FEV1, HRCT ﬁnding and other laboratory
investigations in all COPD patients.
GOLD stage FEV1 HRCT Sputum C/S Eosinophilic count Leucocytic count Hematocrit value Neutrophil count
r 0.03 0.25 0.5 0.3 0.07 0.1 0.06 0.05
p >0.05 >0.05 <0.001 <0.05 >0.05 >0.05 >0.05 >0.05
IgE and COPD 577There are several limitations to our study, the diagnosis of
aspergillosis was based on sputum culture. We did not analyze
the difference in long-term drug therapy, particularly inhaled
corticosteroids in these patients. Medication use and compli-
ance of the patients may affect symptoms and lung function,
although it is possible to have a similar effect on levels of
serum IgE. The time interval between exacerbations was not
analyzed.
Conclusions
There was a high prevalence of elevated serum T-IgE in
patients with COPD but without obvious atopy. Serum T-
IgE levels were found to be associated with symptoms such
as dyspnea and impairment of lung function. Recurrent
exacerbation of COPD is believed to accelerate disease pro-
gression and impairment of pulmonary function.
Acute exacerbation of COPD can be precipitated by several
factors, but the most common causes appear to be viral or bac-
terial respiratory infections [5]. However, the cause of about
one-third of severe exacerbations of COPD cannot be identi-
ﬁed [5] because the allergic phenotype of COPD was shown
to have an increased risk of exacerbations.
Finally, longitudinal studies may also be needed to examine
the potential role of allergy in disease expression or progres-
sion of COPD.Conﬂict of interest
We have no conﬂict of interest to declare.References
[1] M.K. Han, A. Agusti, P.M. Calverley, B.R. Celli, G. Criner, J.L.
Curtis, L.M. Fabbri, J.G. Goldin, P.W. Jones, W. Macnee, B.J.
Make, K.F. Rabe, S.I. Rennard, F.C. Sciurba, E.K. Silverman,
J. Vestbo, G.R. Washko, E.F. Wouters, F.J. Martinez, Chronic
obstructive pulmonary disease phenotypes: the future of COPD,
Am. J. Respir. Crit. Care Med. 182 (2010) 598–604.
[2] C.J. Murray, A.D. Lopez (Eds.), The global burden of disease: a
comprehensive assessment of mortality and disability from
diseases, injuries and risk factors in 1990, and projected to
2020, Cambridge, MA, 1996, pp. 361–395.
[3] S.K. Jindal, Emergence of chronic obstructive pulmonary
disease as an epidemic in India, Indian J. Med. Res. 124
(2006) 619–630.
[4] C.R. Jenkins, G.B. Marks, H.K. Reddel, Traditional and
patient-centred outcomes with three classes of asthma
medication, Eur. Respir. J. 26 (2005) 36–44.
[5] Global initiative of chronic obstructive lung disease:
global strategy for the diagnosis and management and
prevention of chronic obstructive lung disease, 2014. Availablefrom: <http://www.goldcopd.com/guidelines-global-strategy-
for-diagnosismanagement.html> (accessed September 2014).
[6] B.R. Celli, P.J. Barnes, Exacerbations of chronic obstructive
pulmonary disease, Eur. Respir. J. 29 (2007) 1224–1238.
[7] K. Nishimurak, T. Izumi, M. Tsukino, T. Oga, Dyspnea is a
better predictor of 5-year survival than airway obstruction in
patients with COPD, Chest 121 (2002) 1434–1440.
[8] H.J. Schwartz, P.A. Greenberger, The prevalence of allergic
bronchopulmonary aspergillosis in patients with asthma,
determined by serologic and radiologic criteria in patients at
risk, J. Lab. Clin. Med. 117 (1991) 138–142.
[9] M. Mahdavinia, L.C. Grammer, Management of allergic
bronchopulmonary aspergillosis: a review and update, Ther.
Adv. Respir. Dis. 6 (2012) 173–187.
[10] D.J. Gottlieb, D. Sparrow, G.T. O’Connor, S.T. Weiss, Skin test
reactivity to common aeroallergens and decline of lung function:
the normative aging study, Am. J. Respir. Crit. Care Med. 153
(1996) 561–566.
[11] H. Masuko, T. Sakamoto, Y. Kaneko, H. Iijima, T. Naito, E.
Noguchi, T. Hirota, M. Tamari, N. Hizawa, Lower FEV1 in
non-COPD, nonasthmatic subjects: association with smoking,
annual decline in FEV1, total IgE levels, and TSLP genotypes,
Int. J. Chronic Obstruct. Pulmon. Dis. 6 (2011) 181–189.
[12] A.J. Frew, S.M. Kennedy, M. Chan-Yeung, Methacholine
responsiveness, smoking, and atopy as risk factors for
accelerated FEV1 decline in male working populations, Am.
Rev. Respir. Dis. 146 (1992) 878–883.
[13] D.P. Tashkin, M.D. Altose, J.E. Connett, R.E. Kanner, W.W.
Lee, R.A. Wise, Methacholine predicts changes in lung function
over time in smokers with early chronic obstructive pulmonary
disease. The Lung Health Study Research Group, Am. J. Respir.
Crit. Care Med. 153 (1996) 1802–1811.
[14] R. Agarwal, A. Chakrabarti, A. Shah, D. Gupta, J.F. Meis, R.
Guleria, R. Moss, D.W. Denning, ABPA Complicating Asthma
ISHAM Working Group: allergic bronchopulmonary
aspergillosis: review of literature and proposal of new
diagnostic and classiﬁcation criteria, Clin. Exp. Allergy 43
(2013) 850–873.
[15] G.T. O’Connor, D. Sparrow, S.T. Weiss, The role of allergy and
nonspeciﬁc airway hyperresponsiveness in the pathogenesis of
chronic obstructive pulmonary disease, Am. Rev. Respir. Dis.
140 (1989) 225–252.
[16] D.B. Jamieson, E.C. Matsui, A. Belli, M.C. McCormack, E.
Peng, S. Pierre-Louis, J. Curtin-Brosnan, P.N. Breysse, G.B.
Diette, N.N. Hansel, Effects of allergic phenotype on respiratory
symptoms and exacerbations in patients with chronic
obstructive pulmonary disease, Am. J. Respir. Crit. Care Med.
188 (2013) 187–192.
[17] M. Bafadhel, S. McKenna, J. Agbetile, A. Fairs, D. Desai, V.
Mistry, J.P. Morley, M. Pancholi, I.D. Pavord, A.J. Wardlaw,
C.H. Pashley, C.E. Brightling, Aspergillus fumigatus during
stable state and exacerbations of COPD, Eur. Respir. J. 43
(2014) 64–71.
[18] A. Bourdin, I. Serre, H. Flamme, P. Vic, D. Neveu, P. Aubas, P.
Godard, P. Chanez, Can endobronchial biopsy analysis be
recommended to discriminate between asthma and COPD in
routine practice?, Thorax 59 (2004) 488–493
